Discontinuation of the Clozapine Risk Evaluation and Mitigation Strategy and Implications in Movement Disorders

Authors

Institutions

Publication Details

Journal
Movement Disorders Clinical Practice
Published
2025-06-28
DOI
https://doi.org/10.1002/mdc3.70197
Citations
1
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discontinuation of the Clozapine Risk Evaluation and Mitigation Strategy and Implications in Movement Disorders

Charles Palmer, Alexander McClanahan, Federico Rodríguez‐Porcel
1 citations
Movement Disorders Clinical Practice
Parkinson's Disease Mechanisms and Treatments
1.39
article

Discontinuation of the Clozapine Risk Evaluation and Mitigation Strategy and Implications in Movement Disorders

Charles Palmer, Alexander McClanahan, Federico Rodríguez‐Porcel
article en
1 citations

Abstract

No abstract available for this paper.
Movement Disorders Clinical PracticeVol. 12(12)
Medical University of South Carolina (US)
Openalex Percentile: Top 18%
Parkinson's Disease Mechanisms and Treatments
1.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Discontinuation of the Clozapine Risk Evaluation and Mitigation Strategy and Implications in Movement Disorders — Charles Palmer, Alexander McClanahan, et al. · Movement Disorders Clinical Practice (2025) | TGRS Research Map | TGRS